European Journal of Cancer
Volume 46, Issue 1 , Pages 170-179 , January 2010

Autoantibody profiling to identify biomarkers of key pathogenic pathways in mucinous ovarian cancer

  • Liangdan Tang

      Affiliations

    • Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women’s Hospital, Boston, MA 02115, USA
    • Present address: Department of Obstetrics and Gynecology, The First Affiliated Hospital of Chongqing Medical University, No. 1 Yixue Yuan Road, Yuzhong District, Chongqing 400016, PR China.
    • ,
  • Junzheng Yang

      Affiliations

    • Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women’s Hospital, Boston, MA 02115, USA
    • ,
  • Shu-Kay Ng

      Affiliations

    • School of Medicine, Griffith University, Meadowbrook, QLD4131, Australia
    • ,
  • Noah Rodriguez

      Affiliations

    • Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women’s Hospital, Boston, MA 02115, USA
    • ,
  • Pui-Wah Choi

      Affiliations

    • Department of Biochemistry, Chinese University of Hong Kong, Hong Kong, China
    • ,
  • Allison Vitonis

      Affiliations

    • Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women’s Hospital, Boston, MA 02115, USA
    • ,
  • Kui Wang

      Affiliations

    • Department of Mathematics, University of Queensland, Brisbane, QLD4072, Australia
    • ,
  • Geoffrey J. McLachlan

      Affiliations

    • Department of Mathematics, University of Queensland, Brisbane, QLD4072, Australia
    • ,
  • Robert J. Caiazzo Jr.

      Affiliations

    • The Molecular Urology Laboratory, Division of Urology, Brigham and Women’s Hospital, Boston, MA 02115, USA
    • ,
  • Brian C.-S. Liu

      Affiliations

    • The Molecular Urology Laboratory, Division of Urology, Brigham and Women’s Hospital, Boston, MA 02115, USA
    • ,
  • William R. Welch

      Affiliations

    • Department of Pathology, Brigham and Women’s Hospital, Boston, MA 02115, USA
    • ,
  • Daniel W. Cramer

      Affiliations

    • Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women’s Hospital, Boston, MA 02115, USA
    • ,
  • Ross S. Berkowitz

      Affiliations

    • Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women’s Hospital, Boston, MA 02115, USA
    • ,
  • Shu-Wing Ng

      Affiliations

    • Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women’s Hospital, Boston, MA 02115, USA
    • Corresponding Author InformationCorresponding author: Address: Laboratory of Gynecologic Oncology, 221 Longwood Avenue, Brigham and Women’s Hospital, Boston, MA 02115, USA. Tel.: +1 617 278 0072; fax: +1 617 975 0856.

Received 11 September 2009 ,Accepted 1 October 2009.

References 

  1. American Cancer Society. Cancer facts and figures. American Cancer Society, Inc; 2004.
  2. Bast RC, Boyer CM, Olt GJ, et al. Identification of marker for early detection of epithelial ovarian cancer. London, England: Chapman and Hall; 1990;
  3. Serov SF, Scullt RE. Histological typing of ovarian tumors. Geneva: World Health Organization; 1993;
  4. Vergote I, De Brabanter J, Fyles A, et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet. 2001;357(9251):176–182
  5. Harrison ML, Jameson C, Gore ME. Mucinous ovarian cancer. Int J Gynecol Cancer. 2008;18(2):209–214
  6. Puls LE, Powell DE, DePriest PD, et al. Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma. Gynecol Oncol. 1992;47(1):53–57
  7. Ichikawa Y, Nishida M, Suzuki H, et al. Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors. Cancer Res. 1994;54(1):33–35
  8. Mok SC, Bell DA, Knapp RC, et al. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res. 1993;53(7):1489–1492
  9. Wamunyokoli FW, Bonome T, Lee JY, et al. Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance. Clin Cancer Res. 2006;12(3 Pt 1):690–700
  10. Hess V, A’Hern R, Nasiri N, et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol. 2004;22(6):1040–1044
  11. Marchbanks PA, Wilson H, Bastos E, et al. Cigarette smoking and epithelial ovarian cancer by histologic type. Obstet Gynecol. 2000;95(2):255–260
  12. Modugno F, Ness RB, Cottreau CM. Cigarette smoking and the risk of mucinous and nonmucinous epithelial ovarian cancer. Epidemiology. 2002;13(4):467–471
  13. Zhang Y, Coogan PF, Palmer JR, Strom BL, Rosenberg L. Cigarette smoking and increased risk of mucinous epithelial ovarian cancer. Am J Epidemiol. 2004;159(2):133–139
  14. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807–1812
  15. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321(5897):1801–1806
  16. Chinni SR, Falchetto R, Gercel-Taylor C, et al. Humoral immune responses to cathepsin D and glucose-regulated protein 78 in ovarian cancer patients. Clin Cancer Res. 1997;3(9):1557–1564
  17. Korneeva I, Bongiovanni AM, Girotra M, Caputo TA, Witkin SS. Serum antibodies to the 27-kd heat shock protein in women with gynecologic cancers. Am J Obstet Gynecol. 2000;183(1):18–21
  18. Gnjatic S, Atanackovic D, Jager E, et al. Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc Natl Acad Sci USA. 2003;100(15):8862–8867
  19. Frenkel K, Karkoszka J, Glassman T, et al. Serum autoantibodies recognizing 5-hydroxymethyl-2’-deoxyuridine, an oxidized DNA base, as biomarkers of cancer risk in women. Cancer Epidemiol Biomarkers Prev. 1998;7(1):49–57
  20. Hu JJ, Chi CX, Frenkel K, et al. Alpha-tocopherol dietary supplement decreases titers of antibody against 5-hydroxymethyl-2’-deoxyuridine (HMdU). Cancer Epidemiol Biomarkers Prev. 1999;8(8):693–698
  21. Lubin R, Zalcman G, Bouchet L, et al. Serum p53 antibodies as early markers of lung cancer. Nat Med. 1995;1(7):701–702
  22. Caron M, Choquet-Kastylevsky G, Joubert-Caron R. Cancer immunomics using autoantibody signatures for biomarker discovery. Mol Cell Proteomics. 2007;6(7):1115–1122
  23. Wang Y, Han KJ, Pang XW, et al. Large scale identification of human hepatocellular carcinoma-associated antigens by autoantibodies. J Immunol. 2002;169(2):1102–1109
  24. Hudson ME, Pozdnyakova I, Haines K, Mor G, Snyder M. Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays. Proc Natl Acad Sci USA. 2007;104(44):17494–17499
  25. Hong SH, Misek DE, Wang H, et al. An autoantibody-mediated immune response to calreticulin isoforms in pancreatic cancer. Cancer Res. 2004;64(15):5504–5510
  26. Tomaino B, Cappello P, Capello M, et al. Autoantibody signature in human ductal pancreatic adenocarcinoma. J Proteome Res. 2007;6(10):4025–4031
  27. Madoz-Gurpide J, Kuick R, Wang H, Misek DE, Hanash SM. Integral protein microarrays for the identification of lung cancer antigens in sera that induce a humoral immune response. Mol Cell Proteomics. 2008;7(2):268–281
  28. Ehrlich JR, Qin S, Liu BC. The ‘reverse capture’ autoantibody microarray: a native antigen-based platform for autoantibody profiling. Nat Protoc. 2006;1(1):452–460
  29. Ehrlich JR, Tang L, Caiazzo RJ, et al. The reverse capture autoantibody microarray: an innovative approach to profiling the autoantibody response to tissue-derived native antigens. In:  Ehrlich JR,  Liu BC editor. Tissue proteomics – pathways, biomarkers, and drug discovery. New Jersey: Humana Press; 2008;p. 175–192
  30. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA. 2001;98(9):5116–5121
  31. McLachlan GJ, Bean RW, Jones LB. A simple implementation of a normal mixture approach to differential gene expression in multiclass microarrays. Bioinformatics. 2006;22(13):1608–1615
  32. Qin S, Qiu W, Ehrlich JR, et al. Development of a “reverse capture” autoantibody microarray for studies of antigen–autoantibody profiling. Proteomics. 2006;6(10):3199–3209
  33. Dennis G, Sherman BT, Hosack DA, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003;4(5):P3
  34. Tatsumi T, Herrem CJ, Olson WC, et al. Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res. 2003;63(15):4481–4489
  35. Zhang J, Chan EK. Autoantibodies to IGF-II mRNA binding protein p62 and overexpression of p62 in human hepatocellular carcinoma. Autoimmun Rev. 2002;1(3):146–153
  36. Chatterjee M, Mohapatra S, Ionan A, et al. Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer Res. 2006;66(2):1181–1190
  37. Lang GA, Yeaman GR. Autoantibodies in endometriosis sera recognize a Thomsen–Friedenreich-like carbohydrate antigen. J Autoimmun. 2001;16(2):151–161
  38. Yeaman GR, Collins JE, Lang GA. Autoantibody responses to carbohydrate epitopes in endometriosis. Ann N Y Acad Sci. 2002;955:174–182[discussion 199–200, 396–406]
  39. Novak A, Dedhar S. Signaling through beta-catenin and Lef/Tcf. Cell Mol Life Sci. 1999;56(5–6):523–537
  40. Shield K, Riley C, Quinn MA, et al. Alpha2beta1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis. J Carcinog. 2007;6:11
  41. Ahmed N, Riley C, Rice G, Quinn M. Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment. Clin Exp Metastasis. 2005;22(5):391–402
  42. Kishikawa T, Sakamoto M, Ino Y, et al. Two distinct patterns of peritoneal involvement shown by in vitro and in vivo ovarian cancer dissemination models. Invasion Metastasis. 1995;15(1–2):11–21
  43. Sarrio D, Moreno-Bueno G, Sanchez-Estevez C, et al. Expression of cadherins and catenins correlates with distinct histologic types of ovarian carcinomas. Hum Pathol. 2006;37(8):1042–1049
  44. Kildal W, Risberg B, Abeler VM, et al. Beta-catenin expression, DNA ploidy and clinicopathological features in ovarian cancer: a study in 253 patients. Eur J Cancer. 2005;41(8):1127–1134
  45. Marzo N, Ortega S, Stratmann T, et al. Cyclin-dependent kinase 4 hyperactivity promotes autoreactivity in the immune system but protects pancreatic cell mass from autoimmune destruction in the nonobese diabetic mouse model. J Immunol. 2008;180(2):1189–1198
  46. Yang YG, Lindahl T, Barnes DE. Trex1 exonuclease degrades ssDNA to prevent chronic checkpoint activation and autoimmune disease. Cell. 2007;131(5):873–886
  47. Hur JW, Sung YK, Shin HD, et al. TREX1 polymorphisms associated with autoantibodies in patients with systemic lupus erythematosus. Rheumatol Int. 2008;28(8):783–789
  48. Delunardo F, Conti F, Margutti P, et al. Identification and characterization of the carboxy-terminal region of Sip-1, a novel autoantigen in Behcet’s disease. Arthritis Res Ther. 2006;8(3):R71

PII: S0959-8049(09)00728-X

doi: 10.1016/j.ejca.2009.10.003

European Journal of Cancer
Volume 46, Issue 1 , Pages 170-179 , January 2010

Article Tools

* Image Usage & Resolution